RVMD Revolution Medicines Inc

Price (delayed)

$190.74

Market cap

$40.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.85

Enterprise value

$41.25B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of ...

Highlights
The company's equity has surged by 74% QoQ and by 40% YoY
RVMD's quick ratio has surged by 69% since the previous quarter but it is down by 4% year-on-year
The debt has soared by 172% from the previous quarter
Revolution Medicines's net income has plunged by 118% YoY and by 29% from the previous quarter

Key stats

What are the main financial stats of RVMD

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
-1.1%
1 week
-2.64%
1 month
-8.94%
1 year
331.49%
YTD
139.47%
QTD
1.85%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$1.63B
Net income
-$1.77B
Gross margin
N/A
Net margin
N/A
Revolution Medicines's net income has plunged by 118% YoY and by 29% from the previous quarter
RVMD's operating income has dropped by 81% year-on-year and by 17% since the previous quarter

Price vs fundamentals

How does RVMD's price correlate with its fundamentals

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
15.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 96% year-on-year and by 25% since the previous quarter
The company's equity has surged by 74% QoQ and by 40% YoY
The P/B is 46% higher than the last 4 quarters average of 10.8

Efficiency

How efficient is Revolution Medicines business performance
Revolution Medicines's return on equity has shrunk by 131% YoY and by 16% QoQ
RVMD's ROA has shrunk by 78% YoY and by 7% QoQ
RVMD's ROIC has dropped by 52% year-on-year

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
RVMD's total assets is 152% greater than its total liabilities
Revolution Medicines's total liabilities has soared by 128% from the previous quarter
RVMD's total assets has soared by 92% since the previous quarter and by 78% year-on-year
The debt is 54% less than the equity
The debt has soared by 172% from the previous quarter
The debt to equity has soared by 130% YoY and by 59% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.